Last reviewed · How we verify

Gastroesophageal reflux disease — Treatment Landscape & Competitive Intelligence

Gastroesophageal reflux disease (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Gastroesophageal reflux disease, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Dexilant DEXLANSOPRAZOLE Takeda Proton Pump Inhibitor [EPC] (H+, K+)-ATPase 2009-01-01
Nexium esomeprazole AstraZeneca Proton pump inhibitor (PPI) Potassium-transporting ATPase 2001-02-20
Protonix pantoprazole Generic (originally Byk Gulden/Altana/Nycomed) Proton pump inhibitor (PPI) ATP-binding cassette sub-family G member 2, Fatty acid synthase, Multidrug and toxin extrusion protein 1 2000-02-02
Pantoprazole Sodium Pantoprazole Sodium Pfizer Proton pump inhibitor (PPI) (H+, K+)-ATPase enzyme 2000-01-01
Aciphex rabeprazole Waylis Proton Pump Inhibitor Potassium-transporting ATPase 1999-01-01
Prevacid lansoprazole Generic (originally Takeda) Proton pump inhibitor (PPI) ATP-binding cassette sub-family G member 2, Cytochrome P450 2C19, Cytosolic endo-beta-N-acetylglucosaminidase 1995-05-10
Renacidin MAGNESIUM CARBONATE United Guardian Vitamin C [EPC] 1990-01-01
Prilosec omeprazole AstraZeneca (originally Astra AB) Proton pump inhibitor (PPI) ATP-binding cassette sub-family G member 2, Cytochrome P450 1A2, Cytochrome P450 2C19 1989-09-14
Pepcid famotidine Generic (originally Yamanouchi/Merck) Histamine-2 Receptor Antagonist [EPC] Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Solute carrier family 22 member 2 1986-10-01
Zantac ranitidine GSK (originally Glaxo) H2 receptor antagonist Multidrug and toxin extrusion protein 1, Acetylcholinesterase, Histamine H2 receptor 1983-06-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 8 drugs in Gastroesophageal reflux disease
  2. Hikma · 2 drugs in Gastroesophageal reflux disease
  3. Sanofi · 2 drugs in Gastroesophageal reflux disease
  4. B Braun · 1 drug in Gastroesophageal reflux disease
  5. Chang Gung Memorial Hospital · 1 drug in Gastroesophageal reflux disease
  6. GSK (originally Glaxo) · 1 drug in Gastroesophageal reflux disease
  7. Generic (multiple manufacturers) · 1 drug in Gastroesophageal reflux disease
  8. Generic (originally Byk Gulden/Altana/Nycomed) · 1 drug in Gastroesophageal reflux disease
  9. Generic (originally Takeda) · 1 drug in Gastroesophageal reflux disease
  10. Generic (originally Yamanouchi/Merck) · 1 drug in Gastroesophageal reflux disease
  11. Genuine Research Center, Egypt · 1 drug in Gastroesophageal reflux disease
  12. Institute of Liver and Biliary Sciences, India · 1 drug in Gastroesophageal reflux disease

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Gastroesophageal reflux disease:

Cite this brief

Drug Landscape (2026). Gastroesophageal reflux disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/gastroesophageal-reflux-disease. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing